Biotech Values

[biomaven0]

This is a good discussion, but I think the LOXO task is generally much harder than BPMC's, at least in the near term.

For BPMC, all the patients with SM or GIST will get tested - those are going to constitute by far the majority of their potential population.

RET I think at this point is pretty much a given seeing that all NSCLC patients should be tested for ALK and it's a no-brainer to add RET.

Neogenomics might actually be the long-term play here.